You just read:

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

News provided by

Eiger BioPharmaceuticals, Inc.

15 May, 2017, 08:00 ET